La Jolla Pharmaceutical
La Jolla Pharmaceutical's chronic kidney disease drug hit its primary endpoint of improving organ function in a Phase II trial, the company said, and while the results sent the biotech's shares skyward by 75%, a quirk in dosing gave some analysts pause.
La Jolla Pharmaceutical is running out of options. Few shareholders bothered to even respond to its latest effort at a merger, and now the one-time high flyer says that its shares will be delisted
La Jolla Pharmaceutical is trying hard to get its investors' attention. In order to complete a proposed merger with Adamis Pharmaceuticals, it has to get an endorsement from the holders of at least
In April, La Jolla Pharmaceutical warned that if it wasn't able to raise funds, a merger, license agreement or other collaboration, it would have to liquidate. And with no "knight in shining armor"
La Jolla Pharmaceuticals is on the edge of the abyss after announcing in February that it's lupus drug Riquent was a bust. Not long after that the company cut an unspecified number of jobs and said
Just a few months after paying La Jolla Pharmaceutical $7.5 million while buying another $7.5 million in its stock, BioMarin Pharmaceutical has returned its rights to Riquent, which recently failed a
Following last week's announcement that it's lead drug failed a Phase III trial, La Jolla Pharmaceutical announced that it is taking steps to preserve its cash, including a "substantial reduction"
Investors swiftly wiped out 82 percent of La Jolla Pharmaceutical's stock value after learning that its lupus drug--Riquent--was being shelved after an interim analysis revealed negative late-stage
BioMarin Pharmaceuticals is betting that the third late-stage trial will be the charm for Riquent, La Jolla Pharmaceutical's experimental therapy for lupus. BioMarin has agreed to pay up to $289